ARCA biopharma provides monetary and Gencaro NDA update ARCA biopharma.

The Company ended the third one fourth of 2009 with $10.6 million in cash and cash equivalents. Due to recent actions to reduce operating expenses and corporate liabilities, the ongoing firm believes that its cash and cash equivalents are adequate to fund operations, at its current price structure, through at least the initial quarter of 2010. The Company is also evaluating other potential financing sources including equity capital and authorities grant funding.. ARCA biopharma provides monetary and Gencaro NDA update ARCA biopharma, Inc. today announced its prepared next steps in response to the May 29, 2009 Complete Response Letter from the U.S.This promising bipartisan expenses would increase vital access and reimbursement for obesity screening and counseling services across disciplines for Medicare patients. Beneficiaries would also gain improved insurance of new prescription medications for chronic obesity administration, Connor said. We are proud to say there is definitely significant support in both houses of Congress and in both parties to make sure patients with obesity get access to the treatment they need and deserve, Connor stated. The need for coordinated care is getting momentum throughout the health care community. Within the last 12 months, the American Center Association, American University of Cardiology and The Obesity Culture publicly declared the necessity for treating the whole individual by leveraging a number of effective obesity treatment modalities.